Form 8-K - Current report:
SEC Accession No. 0001193125-25-084340
Filing Date
2025-04-17
Accepted
2025-04-17 16:14:46
Documents
14
Period of Report
2025-04-16
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d940643d8k.htm   iXBRL 8-K 30535
2 EX-16.1 d940643dex161.htm EX-16.1 2251
  Complete submission text file 0001193125-25-084340.txt   161045

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rntx-20250416.xsd EX-101.SCH 2857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rntx-20250416_lab.xml EX-101.LAB 18758
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rntx-20250416_pre.xml EX-101.PRE 11715
17 EXTRACTED XBRL INSTANCE DOCUMENT d940643d8k_htm.xml XML 3811
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Rein Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

EIN.: 134196017 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38130 | Film No.: 25847477
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)